SCHEMBL4215664

SCHEMBL4215664

O=C(O)c1ccc(-c2ccccc2)cc1Nc1ccc(F)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACLY P53396 7/20 0.52
BCL2L1 Q07817 1/20 0.51
BAD Q92934 1/20 0.51
XDH P47989 1/20 0.51
SLC22A12 Q96S37 1/20 0.51
AKR1C3 P42330 3/20 0.50
AKR1C2 P52895 3/20 0.50
CDC7 O00311 1/20 0.50
DAPK3 O43293 1/20 0.50
PAK4 O96013 1/20 0.50
PIM1 P11309 1/20 0.50
CDK2 P24941 1/20 0.50
FLT3 P36888 1/20 0.50
GSK3B P49841 1/20 0.50
CDK9 P50750 1/20 0.50
CDK5 Q00535 1/20 0.50
DYRK1A Q13627 1/20 0.50
MELK Q14680 1/20 0.50
MINK1 Q8N4C8 1/20 0.50
HIPK2 Q9H2X6 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4226484 0.95 XDH (0.54) ACLYBCL2L1BADXDHSLC22A12
SCHEMBL4222990 0.92 ACLY (0.59) ACLYAKR1C3AKR1C2GRIK1MAPT
SCHEMBL4217388 0.92 DCLRE1B (0.53) ACLYBCL2L1BADXDHSLC22A12
SCHEMBL4216089 0.90 XDH (0.53) ACLYXDHSLC22A12AKR1C3AKR1C2
SCHEMBL4223119 0.89 AKR1C3 (0.60) ACLYAKR1C3AKR1C2GRIK1MAPT
SCHEMBL4223004 0.89 XDH (0.50) ACLYBCL2L1BADXDHSLC22A12
SCHEMBL4223054 0.89 AKR1C3 (0.59) ACLYXDHSLC22A12AKR1C3AKR1C2
SCHEMBL4216624 0.89 GRIK1 (0.58) ACLYXDHSLC22A12AKR1C3AKR1C2
SCHEMBL4215681 0.88 GRIK1 (0.54) ACLYXDHSLC22A12AKR1C3AKR1C2
SCHEMBL4213884 0.88 MCL1 (0.56) ACLYXDHSLC22A12AKR1C3AKR1C2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8327467-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2012-12-11 US disclosed
US-8327467-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2012-12-11 US disclosed
US-8327467-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2012-12-11 US disclosed
EP-1860098-B1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO LTD (JP) 2012-11-14 EP disclosed
US-20090105474-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-04-23 US disclosed
US-20090105474-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-04-23 US disclosed
US-20090105474-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-04-23 US disclosed
EP-1860098-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-11-28 EP disclosed
EP-1860098-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-11-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105474-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF MMP13, MMP11, MMP3 ACLY 430/4885BCL2L1 1327/4885BAD 1530/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.